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the involvement of these metals in MS lesion pathogenesis. 
We found that the distribution of iron and zinc is heteroge-
neous in MS plaques, and with few remarkable exceptions 
they do not accumulate in chronic MS lesions. We show 
that brain iron tends to decrease with increasing age and 
disease duration of MS patients; reactive astrocytes organ-
ized in large astrogliotic areas in a subset of smoldering and 
inactive plaques accumulate iron and safely store it in fer-
ritin; a subset of smoldering lesions do not contain a rim of 
iron-loaded macrophages/microglia; and the iron content of 
shadow plaques varies with the stage of remyelination. Zinc 
in MS lesions was generally decreased, paralleling myelin 
loss. Iron accumulates concentrically in a subset of chronic 
inactive lesions suggesting that not all iron rims around MS 
lesions equate with smoldering plaques. Upon degeneration 
Abstract Multiple sclerosis (MS) is a chronic inflamma-
tory demyelinating disease of the central nervous system 
(CNS) in which oligodendrocytes, the CNS cells that stain 
most robustly for iron and myelin are the targets of injury. 
Metals are essential for normal CNS functioning, and metal 
imbalances have been linked to demyelination and neuro-
degeneration. Using a multidisciplinary approach involving 
synchrotron techniques, iron histochemistry and immuno-
histochemistry, we compared the distribution and quanti-
fication of iron and zinc in MS lesions to the surrounding 
normal appearing and periplaque white matter, and assessed 
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of iron-loaded microglia/macrophages, astrocytes may 
form an additional protective barrier that may prevent iron-
induced oxidative damage.
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Introduction
Multiple sclerosis (MS) is a central nervous system (CNS) 
chronic inflammatory demyelinating disease which tar-
gets oligodendrocytes and myelin. Oligodendrocytes are 
the CNS cells that stain most robustly for iron [63], and 
are also highly susceptible to inflammatory-mediated 
injury [73]. Metals are essential for the synthesis, stabil-
ity, and maintenance of myelin [14, 29, 36, 63, 64], and 
are required for normal CNS functioning [36, 72]. Metal 
dyshomeostasis causes myelin breakdown in Hunting-
ton disease [4], and hyperzincemia-induced copper defi-
ciency [51]. This suggests an important role for iron and 
other metals, such as zinc, in MS pathogenesis. Iron levels 
in particular must be balanced delicately since loading of 
cells with iron may lead to the formation of reactive oxy-
gen species and oxidative damage of DNA, lipids, and 
proteins.
Oxidative stress, dysregulation of metals and metallo-
proteins in the serum, cerebrospinal fluid or brains of MS 
patients, and iron liberation in the CNS extracellular space 
have been linked to the conversion of isolated demyelinat-
ing episodes to clinically definite MS, as well as to MS 
progression via amplification of demyelination and neuro-
degeneration [22, 27, 31, 56]. While some magnetic reso-
nance imaging (MRI) sequences have been used to image 
iron in vivo in MS [1, 3, 26, 39, 75, 76], histochemistry is 
the gold standard to localize metals in tissue. However, iron 
histochemistry detects only nonheme iron [38], and histo-
chemistry for zinc has poor sensitivity, specificity and is 
complex [15, 32]. Each method employs a different chemi-
cal reaction, and therefore cannot be used on the same tis-
sue section. X-ray fluorescence imaging (XFI) is element-
specific, quantitatively detects all chemical forms of any 
metal and simultaneously maps multiple metals, therefore 
addressing the limitations of histochemistry [45, 46, 48, 49, 
52]. This is the first systematic synchrotron X-ray fluores-
cence study to compare the distribution and quantification 
of iron and zinc in MS lesions to the surrounding normal 
appearing white matter (normal appearing WM) and peri-
plaque white matter (periplaque WM) from a given patient, 




Study approval was granted by the University of Saskatch-
ewan Biomedical Research Ethics Board (Bio# 11-217), 
Mayo Clinic Institutional Review Board (IRB-2067-99), 
and University Medical Center Göttingen ethical review 
committee (14/05/03). We analyzed formalin-fixed paraf-
fin-embedded archival autopsy tissue from 18 MS patients 
(Suppl. Table 1), with no known iron metabolism abnor-
malities. Tissue was embedded in paraffin at autopsy under 
routine neuropathology processing, therefore limiting 
variability between cases with respect to fixation duration. 
Clinical diagnosis was determined according to McDonald 
or Poser criteria by a certified neurologist [37, 50]. Clini-
cal course was defined as acute monophasic MS result-
ing in death within a year, relapsing remitting (RR) MS, 
secondary progressive (SP) MS, primary progressive (PP) 
MS, or uncertain, when insufficient clinical data rendered 
sub-classification not possible [33].
Neuropathology and Immunohistochemistry
A certified neuropathologist confirmed the pathological 
diagnosis of inflammatory demyelination consistent with 
MS. Microscopic sections, 5-μm thick, were stained with 
hematoxylin and eosin for morphological evaluation, Luxol 
fast blue (LFB)/periodic acid–Schiff or LFB/hematoxy-
lin & eosin for myelin, and silver impregnation for axons. 
Iron histochemistry was performed using a DAB-enhanced 
Turnbull staining that detects all nonheme ferric and ferrous 
iron [38], and is therefore the appropriate complementary 
method that enables a direct comparison to XFI. Immuno-
histochemistry was performed using an avidin–biotin tech-
nique using the primary antibodies listed in Suppl. Table 2.
White matter plaques were classified as described previ-
ously [19]. Smoldering plaques showed an inactive demy-
elinated center surrounded by a rim of activated micro-
glia/macrophages containing myelin debris [18]. Inactive 
plaques were completely demyelinated with a sharp border 
and few macrophages/microglia. Completely remyelinated 
(shadow) plaques were sharply circumscribed regions of 
reduced myelin staining. Periplaque and normal appearing 
WM referred to the white matter immediately surrounding 
the demyelinated lesion, or white matter located at least 
2 cm away from the lesion, respectively.
Cortical demyelinated lesions were classified as 
described previously [28, 34]. Leukocortical lesions 
involved both the deeper cortex and subjacent white mat-
ter. Intracortical lesions were centered on blood vessels 
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and confined within the cortex. Subpial lesions extended 
from pia into the deeper cortical layers.
Synchrotron X‑ray fluorescence imaging
Synchrotron XFI was performed at the Stanford 
Synchrotron Radiation Lightsource (SSRL), Stanford 
University, Menlo Park, CA, USA on 15-μm thick 
sections collected on metal-free plastic coverslips (Nunc 
Thermanox, Thermo Scientific, USA). Whole sections 
were imaged on beamline 10-2, mounted at 45° to the 
incident beam (12.5 keV) which passed through a glass 
polycapillary (XOS, USA) to produce a 50 μm × 50 μm 
spot on the sample. The beam exposure time was 80 ms/
pixel. Fluorescent energy windows were centered for iron 
(6.21–6.70 keV) and zinc (8.38–8.98 keV).
Regions of interest (ROI) were imaged at higher 
resolution using the microfocused XFI on beamline 2–3 
with a 3 μm × 3 μm incident X-ray beam (7.15 keV) 
focused with Kirkpatrick–Baez mirrors, and a 120 ms/
pixel dwell time. Fluorescence was normalized against 
the incident X-ray beam intensity to take into account 
its fluctuations. X-ray fluorescence was detected using a 
silicon drift detector (Hitachi) mounted 90° to the incident 
beam utilizing the Xpress3 signal processing system 
(Quantum Detectors, UK).
Histology: XFI correlation and XFI data analysis
Sections stained for proteolipid protein were scanned at 
40× magnification using an Olympus VS110 slide scanner. 
Whole maps were saved as JPEG files on which normal 
appearing and periplaque WM, normal cortex, and lesion 
ROIs were outlined. XFI images were generated using 
MicroTool Kit software [68]. Histology and XFI maps were 
displayed side by side, and XFI ROIs were outlined using 
the histology maps as guides (Suppl. Fig. 1). Normalized 
X-ray fluorescence was obtained for each ROI pixel. 
Data were then imported into R for statistical analysis (R 
Foundation for Statistical Computing, Vienna, http://R-
project.org). The impact of blood metals from large vessels 
was accounted for by excluding them from the ROI at the 
time of quantification.
X‑ray absorption near edge structure
X-ray absorption near edge structure (XANES) spectra of 
ROIs (Suppl. Fig. 2) detected during microfocused XFI 
were acquired on beamline 2–3 equipped with a Si(111) 
double-crystal monochromator from one smoldering and 
one inactive lesion from different patients. The incident 
and transmitted X-ray intensities were monitored using 
N2-filled ionization chambers. The Fe K-edge spectra 
were recorded as K fluorescence excitation spectra using a 
silicon drift detector. The X-ray energy was calibrated to the 
lowest K-edge energy inflection point of a standard iron foil 
(EXAFS Co), whose energy was assumed to be 7111.3 eV. 
Five to seven points of interest (each encompassing a 
7 μm2 area) were randomly sampled from within each 
plaque subregion and averaged to representatively assess 
the chemical form of iron in each subregion (Suppl. Fig. 2). 
Eight to sixteen sweeps were collected for each point 
of interest and averaged to improve the signal to noise 
ratio. Therefore, each spectrum in Figs. 4, 6 and Table 2 
represents an average of 40–90 spectra collected from 5 to 
7 different points of interest (Suppl. Fig. 2).
X‑ray absorption near edge structure data analysis
Data analysis was performed using the EXAFSPAK 
computer program suite (http://ssrl.slac.stanford.edu/
exafspak.html). Quantitative determination of the iron 
chemical forms was carried out by least-squares fitting 
of near-edge spectra to linear combinations of spectra of 
different standards (Suppl. Table 3) [43, 47]. No smoothing 
or related data manipulations were performed.
Statistical analysis
We used a two-stage statistical approach in analyzing 
normalized X-ray fluorescence counts. First, we calculated 
the median normalized metal counts across all pixels in a 
given ROI. The median was used as a measure of central 
tendency that was robust to right skew and possible 
outliers. Second, we fit a linear mixed effects regression 
model using the lme4 package in R with normalized 
counts as the response and treating 7-level region type 
as a random effect. This served to shrink estimates of the 
normalized counts in each region type towards the overall 
average and control false positives [20]. The mixed effects 
models also included a subject-specific random intercept to 
account for intraclass correlation among regions from the 
same individual. Additional analyses examined the effects 
of age and duration using mixed models with a random 
age by region type or duration by region type interaction. 
These models allowed for separate associations with age or 
duration for each region type that were shrunk towards the 
overall average. Quantile-based confidence intervals (CIs) 
were obtained from parametric bootstrap sampling. For 
subset analyses involving only a few subjects we calculated 
a mean normalized intensity for each person averaging over 






Tissues from 18 patients [ten female (56%) and eight 
male patients (44%)] were studied (Suppl. Table 1). The 
median disease duration was 16 years (range 1–42). The 
median age at death was 66 years (range 19–82). Two 
patients (11%) had RRMS, four (22%) SPMS with attacks, 
six (33%) SPMS without attacks, one (6%) PPMS, and 
one (6%) acute monophasic MS. The clinical course was 
unavailable in four (22%).
Twenty-one blocks containing 148 ROIs were analyzed. 
There were 59 lesions: 19 inactive white matter lesions 
(13%), ten smoldering lesions (7%), five shadow plaques 
(3%) and 25 cortical plaques (17%). The remaining 89 
ROIs included nine regions of normal appearing WM, 35 
of periplaque WM, and 45 of normal appearing cortex 
(Table 1).
Relationship between metals and age/disease duration 
in MS
Overall, iron levels decreased with increasing patient 
age (p = 0.03), irrespective of plaque type. For example, 
average iron levels in patients age 60 at death were an 
estimated 15% lower than those age 45 at death (95% CI, 
2–26% lower). There was some variation in the iron vs. age 
relationship by region type (Suppl. Fig. 3a), although this is 
suggestive only since the statistical evidence for differences 
in the correlation by region type is limited. Patients with 
longer disease duration tended to have lower iron across 
regions, although this association did not reach statistical 
significance (p = 0.15) (Suppl. Fig. 4a). There was no 
evidence that zinc varied with age (p = 0.66) (Suppl. 
Fig. 3b) or disease duration (p = 0.49) (Suppl. Fig. 4b).
Iron content of MS lesions
In the white matter, on average the normal appearing 
WM had the highest iron content, followed by the peri-
plaque WM, shadow plaques, inactive and smolder-
ing lesions (Fig. 1a, b, Suppl. Fig. 4c). Iron in normal 
appearing WM was significantly greater than in the peri-
plaque WM (p < 0.001) and all lesion types (p = 0.006 
vs. shadow plaques; p < 0.001 vs. smoldering lesions; 
p < 0.001 vs. inactive lesions). The iron content was similar 
between periplaque WM and shadow plaques (p = 0.89), 
and was significantly increased in periplaque WM and 
shadow plaques when compared to smoldering (p = 0.02; 
p < 0.001) or inactive lesions (p = 0.03; p < 0.001). Inactive 
and smoldering lesions had similar iron levels (p = 0.74).
In the gray matter, the normal appearing cortex had 
significantly elevated iron compared to cortical lesions 
(p = 0.02). (Fig. 1a, b, Suppl. Fig. 4c). The small number 
of leukocortical and intracortical lesions precluded any 
definitive conclusions regarding their iron content.
Zinc content of MS lesions
In the white matter, the normal appearing WM had the 
most zinc, followed by the periplaque WM, shadow 
plaques, inactive and smoldering lesions (Fig. 1a, b, Suppl. 
Fig. 4c). The normal appearing WM had significantly 
increased zinc when compared to all lesion types 
(p = 0.008 vs. shadow plaques; p = 0.001 vs. smoldering 
lesions; p = 0.005 vs. inactive lesions). The difference 
between the normal appearing and periplaque WM was 
not significant (p = 0.29). Zinc in the periplaque WM was 
significantly higher than in smoldering lesions (p = 0.01), 
and to a lesser degree versus other lesion types (p = 0.06 
vs. shadow plaques; p = 0.06 vs. inactive lesions). Zinc 
in inactive lesions was similar to smoldering (p = 0.31) 
and shadow plaques (p = 0.82). There was no significant 
Table 1  The table shows the 
number of subjects, blocks, and 
plaques with each region type
Region type, number (%) Subjects (n = 18) Blocks (n = 21) Regions of interest (n = 148)
White matter tissue
 Normal appearing 5 (28%) 6 (29%) 9 (6%)
 Periplaque 18 (100%) 21 (100%) 35 (24%)
 Inactive plaque 10 (56%) 11 (52%) 19 (13%)
 Smoldering plaque 8 (44%) 9 (43%) 10 (7%)
 Shadow plaque 4 (22%) 4 (19%) 5 (3%)
Cortical tissue
 Normal appearing 16 (89%) 18 (86%) 45 (30%)
 Leukocortical plaque 2 (11%) 2 (10%) 3 (2%)
 Subpial plaque 8 (44%) 9 (43%) 20 (13%)
 Intracortical plaque 2 (11%) 2 (10%) 2 (1%)
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Fig. 1  Iron and zinc in MS lesions; a Distribution of Fe and Zn nor-
malized X-ray fluorescence values for each of the 21 blocks in the 
study. Each point represents one region of interest (ROI) on a par-
ticular block. The value displayed is the median metal divided by the 
incident X-ray beam intensity over the entire ROI multiplied by 100. 
The patient age at death (years) and disease duration (years) are pro-
vided on the y-axis, noting that three patients have two blocks; b Esti-
mated metal content with 95% confidence interval (CI) (dark gray 
lines) and 68% CI (black lines) by plaque type. The two CIs represent 




difference between the zinc content of the smoldering and 
shadow plaques (p = 0.23).
In the gray matter, there were no significant zinc 
differences between the normal appearing cortex and 
cortical lesions (p = 0.39) (Fig. 1a, b, Suppl. Fig. 4c). 
Given the small number of leukocortical and intracortical 
lesions, no definitive conclusion regarding their zinc 
content could be determined.
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Plaque‑specific metal distribution subregion patterns
Smoldering white matter plaques
We identified ten smoldering plaques (Table 1; Fig. 2a, d, 
g) from nine tissue blocks from eight patients (four SPMS, 
three without and one with attacks; one RRMS; three 
with uncertain clinical course) characterized by a variable 
degree of demyelinating activity (Fig. 2a, g insets) at the 
rim. Three smoldering plaques demonstrated a dense mye-
lin-laden macrophage accumulation, whereas seven had 
few macrophages containing myelin debris at the rim. The 
rim of macrophages/microglia (Fig. 2d, g) in 4/10 smolder-
ing plaques contained iron visible on XFI (Figs. 2h, k, 4c). 
The Turnbull stain matched the XFI in three lesions while 
in the fourth it did not demonstrate the iron ring (Fig. 2i, 
l) visible on XFI (Fig. 2h, k-white asterisks). Neither the 
XFI (Fig. 2b) nor the Turnbull stain (Fig. 2f) showed an 
iron-containing rim of activated microglia/macrophages 
in the remaining six smoldering plaques. No zinc was pre-
sent in the rim (Fig. 2c, j, k). Quantitatively, there was no 
significant difference in iron (p = 0.21) or zinc (p = 0.08) 
between the rims and inactive centers of smoldering 
lesions.
The completely demyelinated inactive center (Fig. 2a) 
was devoid of iron in six smoldering lesions, while four 
lesions (three with and one without an iron ring, all from 
patients younger than 50 years of age) contained patchy 
subregions of iron accumulation and iron loss visible on 
XFI (Figs. 2b, h, k, 4a, b), and iron histochemistry (Fig. 2f, 
i). These iron-rich regions located within the inactive 
demyelinated center co-localized with areas of reactive 
astrogliosis and glial scaring (Fig. 2e). Iron within these 
patches was significantly increased when compared to 
the iron in the rest of the demyelinated center (p = 0.02), 
and there was a trend of increase relative to the rim iron 
(p = 0.06), but not compared to the periplaque WM iron 
(p = 0.55). Zinc was low in the inactive demyelinated 
center of smoldering lesions (Fig. 2c), except in one case 
where zinc was increased periventricularly (Fig. 2j).
XFI showed that in 8/10 smoldering plaques, iron in 
the periplaque WM adjacent to the smoldering rim was 
decreased compared to the remote periplaque WM iron 
(Figs. 2b, 4c). Three of these eight lesions had a periplaque 
WM band of very low iron content (Fig. 2k-black 
asterisks, and the corresponding region in Fig. 2h) located 
immediately adjacent to the smoldering rim (Fig. 2h, 
k-white asterisks). Iron histochemistry corresponded 
with XFI in 5/10 smoldering lesions (Fig. 2f), but failed 
to identify the periplaque WM iron decrease and the rim-
adjacent low iron band (Fig. 2i, l) in 5/10 lesions. Zinc 
was preserved in all rim-adjacent periplaque WM regions 
(Fig. 2j, k), except one (Fig. 2c), and was abundant in the 
remote periplaque WM (Fig. 2c, j, k).
Based on XFI, iron histochemistry and 
immunohistochemistry for H-ferritin (FTH) and L-ferritin 
(FTL), we identified five subregions of smoldering plaques:
1. High iron inactive center regions Iron-rich areas within 
the inactive center of smoldering lesions corresponded 
to iron accumulation within reactive astrocytes 
and astrocytic fibers (Figs. 3a, 4a) that abundantly 
expressed FTH (Fig. 3b) and FTL (Fig. 3c).
2. Low iron inactive center regions Regions of tissue 
rarefaction located within the high iron patches, 
and between these and the smoldering rims or the 
periplaque WM, contained sparse small reactive 
astrocytes and thin glial fibers that contained low 
amounts of iron (Figs. 3d, 4b) which expressed 
abundant FTH (Fig. 3e) but little FTL (Fig. 3f).
3. Smoldering rim Iron was present in reactive astrocytes 
(white arrows in Figs. 3g, 4c) and cells resembling 
macrophages (black arrows in Figs. 3g, 4c). These 
cells stained intensely for iron (Fig. 3g, g lower right 
inset), were CD68-immunopositive (Fig. 3i upper 
right inset), GFAP-immunonegative (Fig. 3i lower left 
inset), and dystrophic (Fig. 3g, i insets) [22]. Normal 
appearing macrophages staining faintly for iron was 
also present (Fig. 3g lower left inset). Reactive astro-
cytes stained intensely for iron (Fig. 3g, g right insets) 
and were often in close contact with, and appeared to 
incorporate iron from macrophage remnants (Fig. 3g 
right upper and lower insets). Reactive astrocytes, mac-
Fig. 2  Fe and Zn in smoldering plaques. a–f Case 5, block 2 in 
Fig. 1a: a Demyelination is seen as lack of PLP immunoreactivity; 
inset shows macrophages in the smoldering rim containing myelin 
debris (PLP); b Fe accumulates in the inactive center of smoldering 
lesions (asterisk) (XFI); c The demyelinated lesion lacks Zn (XFI); 
d Macrophages/microglia accumulate at the edge of the smolder-
ing lesion; inset shows higher magnification of the smoldering rim 
(CD68); e Reactive astrocytes and fibrillary gliosis are present in the 
inactive center (asterisk) (GFAP); f Fe accumulates within the inac-
tive center of smoldering lesions (asterisk) (Fe histochemistry); g–l 
Case 4 in Fig. 1a: g The rim of macrophages/microglia is seen at the 
smoldering plaque’s edge (CD68); inset shows that macrophages in 
the smoldering rim contain myelin debris (PLP); h Iron accumulates 
in the inactive center (black asterisk) and to a lesser extent in the rim 
(white asterisks) (XFI); i The Turnbull stain also shows iron accumu-
lation in the inactive center (black asterisk) (Fe histochemistry); j Zn 
is located periventricularly (XFI); k The overlay of Fe and Zn shows 
the iron-accumulating rim of the smoldering plaque (white asterisks) 
and the iron-poor periplaque WM (black asterisks) (XFI); l The Turn-
bull stain does not show the iron-poor periplaque WM (Fe histochem-
istry); Scale bars a–j 3 mm; Scale bars insets a, j 25 μm; Scale bar 
inset d 200 μm; Scale bars k, l 1 mm. Color scales b, c, h, j repre-
sent the normalized total Kα fluorescence counts, proportional to total 
metal present, from blue (lowest) to red (highest); Color scale k rep-
resents the overlay of the normalized total Fe and Zn Kα fluorescence 




rophages, and their remnants were immunoreactive for 
FTH (Fig. 3h), but only the latter were immunoreactive 
for FTL (Fig. 3i). Most oligodendrocytes present in the 
smoldering rim showed pyknotic nuclei consistent with 
apoptosis (Fig. 3h insets), did not stain for iron (Fig. 3h 
lower left inset), were faintly immunoreactive for FTH 
(Fig. 3h) but immunonegative for FTL (Fig. 3i). Iron-
loaded apoptotic oligodendrocytes were occasionally 
observed (Fig. 3h lower right inset).
4. Rim-adjacent periplaque white matter The rim-adja-
cent periplaque WM contained oligodendrocytes 
(Fig. 3j, j lower left inset) and reactive astrocytes 
(Fig. 3j arrows and upper right inset) that did not stain 
for iron. High resolution XFI showed that iron was pre-
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sent in cells in this region (Fig. 4c). Myelin and few 
macrophages/microglia in the smoldering rim-adjacent 
periplaque WM stained for iron (Fig. 3j). Oligodendro-
cytes were immunoreactive for FTH (Fig. 3k). Only 
microglia were immunoreactive for FTL (Fig. 3l).
5. Remote periplaque white matter The remote periplaque 
WM showed the normal iron patchy appearance 
and the U fiber high iron content (Figs. 2b, f, h, i, l, 
4a–c). Most oligodendrocytes (Fig. 3m, m inset) 
and myelin (Fig. 3m) stained intensely for iron. 
Oligodendrocytes were immunoreactive for FTH 
(Fig. 3n) and FTL (Fig. 3o inset), whereas microglia 
were immunoreactive for FTL (Fig. 3o).
XANES analysis across smoldering plaque subregions
Iron K near edge spectra (Suppl. Fig. 2a–c) from these 
five subregions were compared in Fig. 4d–h and Table 2, 
and showed that the highly ordered ferrihydrite of ferritin 
predominated in most samples, except in the high iron 
areas of the smoldering plaque inactive center and the 
smoldering rim, where goethite accounted for about one 
third (30%) and one half (50%), respectively, of all ferric 
oxyhydroxides. Magnetite accounted for 17% of the total 
iron (30% of ferric oxides) present in the remote periplaque 
WM. Heme iron represented an important component in 
the remote periplaque WM (44%), rim-adjacent periplaque 
WM (42%) and low iron inactive center areas (50%), but 
its proportion decreased dramatically in the smoldering rim 
(0%) and high iron areas (24%).
Chronic inactive white matter plaques
We analyzed nineteen inactive demyelinated plaques 
(Table 1; Figs. 5a, 6a, Suppl. Fig. 1a, b, Suppl. Fig. 5a) from 
11 tissue blocks of ten MS patients (six with SPMS, one 
with and five without attacks; one with PPMS; three with 
uncertain course). Eighteen inactive plaques (95%) showed 
iron loss on XFI (Fig. 5c, h, Suppl. Fig. 1c, Suppl. Fig. 5b, 
d) and iron histochemistry (Fig. 5b, Suppl. Fig. 5e). XFI 
showed loss of zinc in inactive lesions (Fig. 5g, h, Suppl. 
Fig. 1d, Suppl. Fig. 5c, d). While iron staining showed iron 
loss in the periplaque WM (Fig. 5b, Suppl. Fig. 5e), XFI 
revealed that periplaque WM iron gradually decreased from 
the normal appearing WM toward the demyelinated lesion 
(Fig. 5c, Suppl. Fig. 1c, Suppl. Fig. 5b). The periplaque 
WM zinc distribution was complex, with loss of zinc lim-
ited to demyelinated areas in some lesions (Fig. 5g, h; 
Suppl. Fig. 1d), but extending to the periplaque WM in oth-
ers (Suppl. Fig. 5c, d). A single inactive lesion revealed a 
ring of increased zinc around the plaque periphery (Suppl. 
Fig. 5c, d) without an obvious pathological correlate. Oli-
godendrocytes were present in the inactive lesions (Fig. 5d) 
and periplaque WM (Fig. 5e), were FTH-immunoreactive, 
but their numbers decreased compared to normal appear-
ing WM (Fig. 5f). In the inactive demyelinated lesions both 
FTL-immunopositive (Fig. 5d upper right inset) and FTL-
immunonegative (Fig. 5d lower left inset) oligodendrocytes 
were present. In periplaque WM, most oligodendrocytes 
were immunonegative for FTL (Fig. 5e inset), while most 
oligodendrocytes in the normal appearing WM were immu-
nopositive for FTL (Fig. 5f inset). 
A single inactive white matter plaque (Fig. 6a) showed 
iron increase on XFI and iron histochemistry in a concentric 
pattern (Fig. 6b). Zinc also had a concentric distribution 
(Fig. 6e). Iron loss areas separated the rings of iron 
accumulation (Fig. 6b). The iron rich regions correlated 
with GFAP (Fig. 6c), but not myelin immunohistochemistry 
(Fig. 6a) or axonal staining (Fig. 6d). Parenchymal and 
perivascular reactive astrocytes (Fig. 6g) accumulated 
iron (Fig. 6f, k, p), and expressed both FTH (Fig. 6h) 
and FTL (Fig. 6i). Iron negative microglia were present 
(Fig. 6j). Reactive astrocytes within the lesion’s low iron 
ring were mildly immunoreactive for FTH (Fig. 6n) and 
FTL (Fig. 6o), but did not stain for iron (Fig. 6m). Iron 
was present in the periplaque and normal appearing WM 
in oligodendrocytes and myelin (Fig. 6l). The myelin had 
a patchy appearance with alternating areas of normal and 
pale myelin (Fig. 6a). Apoptotic oligodendrocytes were 
frequent but did not stain for iron (inset in Fig. 6l).
Fig. 3  The different subregions of smoldering plaques as defined by 
their iron content and metalloprotein expression (Case 4 in Fig. 1a). 
a–c Iron-rich areas of the inactive center: Fe accumulates in astro-
cytes (a, Fe histochemistry) that express H-ferritin (b, FTH) and 
L-ferritin (c, FTL); d–f Iron-poor areas of the inactive center: astro-
cytes still accumulate iron but to a lesser extent (d, Fe histochem-
istry), express abundantly H-ferritin (e, FTH) but little L-ferritin (f, 
FTL); g–i The smoldering rim: iron accumulates in dystrophic mac-
rophages (black arrows, lower right inset) and reactive astrocytes 
(white arrows, lower and upper right insets), but not all macrophages 
accumulate Fe (lower left inset) (g, Fe histochemistry); dystrophic 
macrophages and reactive astrocytes are immunoreactive for H-fer-
ritin (insets show iron-reactive and iron-negative apoptotic oligoden-
drocytes) (h, FTH); dystrophic macrophages, but not reactive astro-
cytes are immunoreactive for L-ferritin (lower left inset shows that 
reactive astrocytes, but not dystrophic macrophages are immunoreac-
tive for GFAP, while the upper right inset shows that dystrophic mac-
rophages, but not reactive astrocytes are immunoreactive for CD68) 
(i, FTL; lower left inset, GFAP; upper right inset, CD68); j–l Rim-
adjacent periplaque WM: iron is present in myelinated axons, but 
not oligodendrocytes (lower left inset) or reactive astrocytes (arrows 
and upper right inset) (j, Fe histochemistry); oligodendrocytes are 
immunoreactive for H-ferritin (k, FTH) and microglia for L-ferritin 
(l, FTL); m–o Remote periplaque WM: oligodendrocytes (inset) and 
myelin stain intensely for iron (m, Fe histochemistry); oligodendro-
cytes are immunoreactive for H-ferritin (n, FTH) and L-ferritin (inset 
in o, FTL), and microglia for L-ferritin (o, FTL); Scale bar 100 μm; 




Similar to the smoldering plaques’ inactive centers, 
the heme iron decreased between the low (21%) and high 
iron (12%) subregions with a concomitant increase in 
ferric iron (79% in low and 88% in high iron subregions), 
consisting entirely of ferritin ferrihydrite (Suppl. Fig. 2d, 
Fig. 6q, r; Table 2).
Fig. 4  Microprobe XFI and XANES analysis of smoldering lesions 
(Case 4 in Fig. 1a): a–c Iron distribution in the various subregions 
of smoldering plaques (XFI); d–h Quantitative analysis of Fe K-edge 
spectra. Each panel shows the normalized spectrum of brain tissue 
(spaced dotted lines) together with the best fit (continuous line). The 
fit components are scaled by their relative contributions: components 
are category as in Table 2. Each category has a unique line type: fer-
rihydrite (dashed line), goethite (single dotted dashed line), magnetite 
(closed dotted lines), heme (double dotted dashed line). See Table 2 
for numerical results of the fits: d Iron-rich subregion of the inactive 
center; e Iron-poor subregion of the inactive center; f Smoldering rim; 
g Rim-adjacent periplaque WM; h Remote periplaque WM. Scale bar 
90 μm; Color scales a–c represent the normalized total Kα fluores-





We found five shadow plaques (Table 1; Fig. 7a, b, g, j 
asterisks) in four tissue blocks from four MS patients (two 
SPMS, one with and one without attacks; one RRMS; one 
with uncertain course). The iron distribution was heteroge-
nous among shadow plaques (even those in the same tissue 
section), with some showing increased iron (Fig. 7c, d, f). 
Low amounts of zinc were present in remyelinated plaques 
(Fig. 7e, f). Shadow plaque iron increase was identified by 
XFI and Turnbull stain (Fig. 7c, d, f). The cells staining most 
robustly for iron were oligodendrocytes with larger nuclei, 
a morphological feature consistent with immature oligoden-
drocytes (Fig. 7h), which stained intensely for FTH (Fig. 7i) 
and FTL (Fig. 7i inset). Reactive astrocytes were present in 
iron-rich shadow plaques and some stained for iron (Fig. 7h 
inset). Mature oligodendrocytes were present in iron-poor 
remyelinated lesions and were immunoreactive for FTH 
(Fig. 7k) and FTL (Fig. 7k inset).
Cortical demyelinated plaques
We identified 25 cortical plaques (20 subpial—Suppl. 
Fig. 6a; 2 intracortical—Suppl. Fig. 6i; 3 leukocortical—
Suppl. Fig. 6 l) in ten patients (four SPMS, one with and 
three without attacks; 1PPMS; 2RRMS; three with uncer-
tain clinical course). Iron in cortical lesions had a tendency 
to be lower than normal appearing cortex (Fig. 1a, b, Suppl. 
Fig. 6b, c, j, m) as previously reported [44, 71]. Iron histo-
chemistry showed almost no iron in cortical lesions (Suppl. 
Fig. 6c) with only few iron positive microglia (Suppl. 
Fig. 6e). However, on XFI iron was decreased but not absent 
(Suppl. Fig. 6b, h, j, m). Oligodendrocytes (Suppl. Fig. 6 g) 
and cortical astrocytes (Suppl. Fig. 6 g inset) were mildly 
immunoreactive for FTH. In the normal appearing cortex, 
oligodendrocytes, myelin, and few microglia stained for 
iron (Suppl. Fig. 6d), while only myelin and oligodendro-
cytes were immunoreactive for FTH (Suppl. Fig. 6f). Micro-
glia were immunoreactive for FTL in lesions and normal 
appearing cortex. Zinc was present in cortical lesions (Suppl. 
Fig. 6 k, n). One leukocortical lesion (case 14 in Fig. 1a) had 
abundant corpora amylacea (Suppl. Fig. 6o) explaining its 
high zinc content (Suppl. Fig. 6n).
Discussion
Our study describes distinct and heterogenous patterns of 
iron and zinc across different chronic MS plaque types. 
With few remarkable exceptions these metals do not 
accumulate in chronic MS lesions. Using cutting edge 
synchrotron techniques that are sensitive and specific 
to detect metals [52], we report for the first time that 
astrocytes in large astrogliotic regions in a subset of 
smoldering and inactive plaques accumulate iron, and 
safely store it as ferrihydrite in ferritin. Furthermore, we 
provide preliminary insights into the complex and dynamic 
relationship of cell-specific iron loading and release and its 
impact on injury and repair over the chronic MS course.
Smoldering plaques represent the most notable example 
of iron accumulation within MS plaques. As smoldering 
plaques are only found among progressive MS patients 
[19], they are an important plaque type to better understand. 
Iron has been reported to accumulate in the microglia/
macrophages, forming the smoldering rim [1, 22, 39] of 
these plaques. We, however, find that not all smoldering 
lesions contain iron-rich microglia/macrophage rims. This 
may relate to varying degrees of smoldering activity at the 
Table 2  Percentage 
contributions a of spectra of iron 
compounds and metalloproteins
a Percentage contribution of iron species to total iron. Precisions, shown in parenthesis, are calculated 
as three times the estimated standard deviation, as derived from the diagonal elements of the covariance 
matrix; best fit using all model spectra in Suppl. Table 3
b Fit error (×10−3) or residual is the average of the sum of the squares of the differences between the 
observed and calculated signals for all data points in the spectrum
Lesion Ferric oxide Heme Fit-errorb
Ferrihydrite Goethite Magnetite
Smoldering
 1. High iron inactive center 57 (1.4) 19 (1.2) 24 (0.6) 0.236
 2. Low iron inactive center 50 (1.8) 50 (1.8) 0.239
 3. Smoldering rim 50 (6) 50 (5) 0.447
 4. Periplaque WM (rim adjacent) 58 (1.3) 42 (1.3) 0.123
 5. Periplaque WM (remote) 39 (6) 17 (7) 44 (10) 0.217
Chronic inactive
 1. High iron 88 (9) 12 (9) 0.828
 2. Low iron 79 (15) 21 (15) 0.179
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plaque edge. We further show that even when an iron-rich 
rim is present, its iron content is not higher than the normal 
appearing WM iron, and is only visible because of the 
iron-poor rim-adjacent periplaque WM separating the two 
regions. The distribution of iron differs between these two 
regions: oligodendrocytes and myelin in normal appearing 
WM stain most intensely for iron [8, 63], whereas iron in 
smoldering rims is localized to dystrophic and normal 
microglia/macrophages [22], as well as to astrocytes.
It has been suggested that the destruction of iron-
loaded oligodendrocytes in MS active lesions may release 
iron extracellularly, where it is subsequently picked up 
by microglia/macrophages. Degeneration of these iron-
loaded microglia/macrophages may induce a second wave 
of iron release, with subsequent axonal iron accumulation, 
oxidative damage and neurodegeneration [22]. While it is 
known that reactive astrocytes incorporate iron [22], we 
describe for the first time that reactive astrocytes forming 
large areas of astrogliosis accumulate iron in a subset of 
MS patients. These iron-rich gliotic patches may represent 
another potential protective barrier the brain mounts when 
faced with degeneration of iron-loaded microglia/mac-
rophages. This is further supported by our finding of astro-
cytes in close contact with, and incorporating iron-reactive 
fragments from iron-loaded macrophages.
Moreover, we observe the highest iron accumulating 
reactive astrogliotic regions in inactive centers of smolder-
ing lesions, further suggesting that reactive astrocytes may 
play an important role in iron uptake and storage in chronic 
MS lesions. This is not surprising since upon inflammatory 
Fig. 5  Iron and zinc in inactive lesions; Case 13 in Fig. 1a: a The 
demyelinated lesion is seen as the lack of myelin immunoreactiv-
ity (PLP); b Iron seems to be lost in the lesion and most periplaque 
WM (Fe histochemistry); c XFI shows that iron is lost in the demyeli-
nated lesion, but gradually decreases in the periplaque WM from the 
normal appearing WM toward the lesion (XFI); d Oligodendrocytes 
are still present in lesions: some are immunoreactive for H-ferritin 
(FTH), and both L-ferritin-immunopositive (upper right inset; FTL) 
and L-ferritin-immunonegative (lower left inset; FTL) oligodendro-
cytes are observed; e Oligodendrocytes and myelinated axons are 
immunoreactive for H-ferritin (FTH) but not L-ferritin (inset, FTL) 
in the periplaque WM; f Oligodendrocytes and myelinated axons 
are immunoreactive for H-ferritin (FTH) and L-ferritin (inset; FTL) 
in the normal appearing WM; g Zn is lost in the demyelinated lesion 
(XFI); h Fe and Zn are both lost in inactive demyelinated lesions, 
while iron is decreased in the normal appearing WM (XFI). Scale 
bars a–c, g, h 3 mm; Scale bars d–f 50 μm; Color scales c, g repre-
sent the normalized total Kα fluorescence counts, proportional to total 
metal present, from blue (lowest) to red (highest); Color scale h rep-
resents the overlay of the normalized total Fe and Zn Kα fluorescence 
counts, proportional to total metal present, from blue (Zn) to red (Fe)
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activation astrocytes elevate their capacity to incorporate 
iron [42, 54, 73], and their ability to resist iron-dependent 
oxidative stress [35]. Immunohistochemistry confirms that 
the iron-loaded astrocytes within these gliotic patches are 
in fact immunoreactive for iron storage proteins, consistent 
with their ability to safely incorporate large amounts of iron 
in ferritin [16]. Furthermore, XANES analysis, although 
limited to two cases, indicates at least half of the iron in 
both the smoldering rims and high-iron gliotic regions 
within the inactive centers of these plaques consists of the 
highly ordered ferrihydrite of ferritin. Surprisingly, a high 
proportion of this accumulated iron represents goethite, the 
predominant iron bio-mineralization component of hae-
mosiderin in thalassaemia [66]. While the mechanism of 
goethite formation is undefined, it is unlikely that it forms 
from ferritin’s ferrihydrite [10, 11]. Iron in goethite is less 
soluble and released less readily than iron of ferritin [2, 40, 
67]. Because XFI cannot distinguish between cell types, it 
is conceivable that astrocytes pick up the goethite already 
biomineralized by macrophages, or they biomineralize the 
iron picked up from macrophages. In either case an impor-
tant proportion of iron is stored as goethite that is even less 
bioavailable and less toxic to cells than iron of ferritin.
The fate of iron-loaded astrocytes in MS lesions is 
unknown. Astrocytes resist iron overload until their anti-
oxidant potential is exhausted [35]. It is possible that while 
astrocytic iron accumulation is protective in the short term, 
incorporating increasing amounts of free iron over time as 
a consequence of continuous inflammatory activity with 
ongoing destruction of iron-loaded oligodendrocytes and 
macrophages will eventually exhaust the astrocytes’ anti-
oxidant defenses, thereby leading to their death. This may 
explain the presence of tissue rarefaction observed sur-
rounding high iron astrocytic patches within the inactive 
center of smoldering plaques. While iron is decreased in 
these tissue-rarefied regions, its chemistry more closely 
resembles that of the periplaque WM with half sheltered 
in ferritin and half associated with heme proteins. The lat-
ter may be hemoproteins that are involved in mitochon-
drial respiration, suggesting a potential metabolic reversal 
of astrocytes from an iron-storage to a normal phenotype. 
Alternatively, the heme observed in rarefied gliotic low iron 
regions may consist of brain globins, which are neuropro-
tective heme-containing proteins [5, 53]. Since XANES 
analysis only interrogates the heme iron, further studies 
will need to elucidate their exact nature, and contribution.
Iron efflux from astrocytes is known to be important for 
remyelination [60]. The iron-induced oxidative destruction 
of iron-loaded astrocytes in a noninflammatory setting 
could provide a double benefit: the removal of the glial scar 
that impairs the migration of oligodendrocyte precursor 
cells into lesions [25], and the release of iron crucial for 
efficient remyelination [63]. Alternatively, astrocytes can 
provide iron to oligodendrocytes through the ferroportin-
ceruloplasmin system [22, 41, 70]. However, in the setting 
of even a minimal inflammatory milieu, as expected in long 
standing chronic MS [18], iron liberation from astrocytes 
would serve to augment oxidative damage rather than 
promote remyelination.
Age and disease duration may contribute to the 
development of iron-rich rims or iron-rich gliotic patches 
observed in a subset of smoldering lesions. All but one of 
the smoldering lesions with an iron rim and all smoldering 
plaques with iron-rich cores were observed in younger 
patients (<50 years old) with less than 15 years disease 
duration. It is possible that younger patients during 
earlier disease stages have more active inflammatory 
disease resulting in more pronounced oligodendrocyte 
destruction with subsequent iron release compared to 
older longstanding patients with less active disease [18]. 
Alternatively, the variable presence of iron rims may reflect 
differences in macrophage polarization [55] or changes in 
macrophage polarization as a result of iron loading [39].
While the majority of chronic inactive lesions showed 
iron loss, one chronic plaque from an elderly patient [62] 
demonstrated concentric rings of iron increase and loss. Iron 
concentration within this lesion resembled the inactive iron-
rich gliotic centers observed among smoldering plaques 
with an accumulation of iron within reactive astrocytes 
immunoreactive for both FTH and FTL, higher ferrihydrite 
concentrations in iron-rich versus iron-poor rings, and a 
concomitant decrease in heme iron. These observations sug-
gest that in some chronic lesions iron safely accumulates in 
ferritin in astrocytes, but not microglia.
Interestingly, in the periplaque WM of most smolder-
ing and chronic inactive plaques, there is a gradient of 
iron loss towards the lesion edge, with three smoldering 
plaques demonstrating a clear ring of iron loss adjacent to 
the smoldering rim. Iron in the periplaque WM is signifi-
cantly lower than iron in the normal appearing WM. While 
iron histochemistry shows that iron-positive myelinated 
axons are present in the periplaque WM, FTH-immunore-
active oligodendrocytes in the periplaque WM do not stain 
for iron. This suggests that oligodendrocytes in the peri-
plaque WM are able to dispose of their iron, a finding com-
patible with previous studies reporting active iron export 
from periplaque WM oligodendrocytes [22]. Iron-loaded 
oligodendrocytes are more vulnerable to cytokine toxic-
ity than iron-depleted oligodendrocytes [73]. Therefore, 
this disposal of iron by periplaque WM oligodendrocytes 
may be a protective, but transient, mechanism oligoden-
drocytes employ when faced with the advancing front of 
inflammation [73]. Microglia may pick up the oligodendro-





of iron loading, increase their release of proinflammatory 
cytokines, thereby switching from a trophic to a toxic phe-
notype [74]. The presence of iron-negative reactive astro-
cytes in the periplaque WM indicates that CNS may be pre-
pared to deal with the potential iron release that ensues.
We have also observed iron-negative FTH immunoreac-
tive oligodendrocytes within inactive demyelinated white 
matter and cortical lesions. While their number is decreased 
compared to the periplaque and normal appearing WM, 
these oligodendrocytes are characterized by normal mor-
phology, suggesting they may be capable of surviving in 
lesions despite the absence of iron.
A lack of iron within oligodendrocytes may impair their 
remyelinating capacity [61, 63]. Previous studies have 
suggested that iron does not accumulate in remyelinated 
plaques [22], and indeed iron was decreased in remyeli-
nated lesions when analyzed as a group. However, when 
examined individually, we found a heterogeneous concen-
tration of iron with some remyelinated plaques display-
ing increased iron. Oligodendrocytes within these shadow 
plaques stained robustly for iron, and were characterized 
by larger nuclei, compatible with an immature phenotype 
[30]. At the other end of the spectrum, we observed remy-
elinated lesions where oligodendrocytes with normal mor-
phology did not stain for iron. These observed differences 
may be explained by differences between early versus 
late remyelination. When remyelination is ongoing, an 
increased amount of iron is required, whereas when remy-
elination is complete, the iron content may decrease to lev-
els at or below those of the normal appearing WM [61, 63].
In addition to iron, zinc is important in the structure and 
compaction of myelin [14, 29, 64]. Zinc is decreased in most 
lesions and its distribution parallels that of myelin. Demy-
elinated white matter lesions are devoid of zinc, and zinc 
decreases in the periplaque WM showing myelin pallor. Only 
three white matter lesions had a moderate zinc increase, but 
their pathologic correlate remains unknown. A single smold-
ering plaque showed increased periventricular zinc, and two 
inactive lesions were characterized by rings of zinc at their 
borders. Cortical lesions showed reduced, but not absent, 
zinc, likely due to the fact that most cortical zinc is concen-
trated in neurons [17]. Zinc was increased in one leukocorti-
cal lesion where it localized to corpora amylacea [65].
We also analyzed the relationship between iron and zinc 
with age and MS disease duration. As part of normal aging, 
iron accumulates in microglia and astrocytes [9], presum-
ably due to a cytokine-induced phenomenon [13]. In MS, 
due to the inflammatory environment [18], iron accumu-
lation is likely accelerated and present already at disease 
onset. It has been reported that iron decreases in the nor-
mal appearing WM of MS patients with increasing disease 
duration, presumably due to the destruction of iron-loaded 
oligodendrocytes [22]. We observed that iron content also 
decreases within MS plaques with increasing age. In con-
trast, neither disease duration, nor age was related to zinc 
content within MS plaques.
Whether there is a role for iron chelation in MS remains 
controversial [12, 61, 69] and is based on the premise that 
iron accumulates in lesions. We have generally observed the 
opposite, as chronic MS plaques tended to be deficient in iron. 
Chelation of these minimal amounts of iron may suppress oli-
godendrocyte metabolic activity and induce cell death [73]. 
Chelation of iron from remyelinating plaques could also be 
detrimental, given the potentially trophic effect of iron and 
ferritin on oligodendrocytes and myelination [58, 74]. How-
ever, oligodendrocytes are still functional in normal white 
matter [9], and survive in chronic and remyelinated lesions, 
as well as periplaque WM despite showing no stainable iron. 
Since iron chelation may not negatively affect all oligodendro-
cytes, it may be considered for the smoldering and chronic MS 
lesions where iron accumulates in astrocytes, macrophages or 
microglia. Removing the iron from iron-filled astrocytes could 
potentially increase their ability to accumulate more iron, 
thereby prolonging their survival. Iron removal from iron-rich 
activated macrophages and microglia in smoldering rims may 
also decrease the release of inflammatory cytokines and pro-
tect oligodendrocytes [74]. Further studies will need to estab-
lish if there is a role for iron chelation in MS given its potential 
detrimental and beneficial effects.
Fig. 6  Iron and zinc in iron accumulating inactive lesions. Case 11 
in Fig. 1a: a The demyelinated lesion is seen as the lack of immu-
noreactivity for myelin (PLP); b Fe accumulates in a concentric pat-
tern in the demyelinated lesion (XFI), and c co-localizes with areas of 
reactive astrocytosis (GFAP), but d not with axonal preservation (sil-
ver impregnation); e Zn is lost in most of the lesion, periplaque and 
normal appearing WM, except a region (arows) at the lesion’s edge 
(XFI); Reactive astrocytes f accumulate iron (Fe histochemistry), and 
are immunoreactive for: g GFAP (GFAP), h H-ferritin (FTH) and i 
L-ferritin (FTL). j Activated microglia are present within the iron-
rich regions of the lesion but do not stain for iron (CD68); k Perivas-
cular astrocytes and the glia limitans stain for iron in these iron rich 
areas (Fe histochemistry); l Both iron-positive and iron-negative 
(inset) oligodendrocytes are present in the normal appearing WM (Fe 
histochemistry); Astrocytes in the low-iron subregions of the inactive 
demyelinated lesions are m negative for iron (Fe histochemistry), n 
but immunoreactive for H-ferritin (FTH) and o L-ferritin (FTL); p 
Iron accumulates perivascularly in astrocytes (XFI); q, r Quantita-
tive analysis of Fe K-edge spectra. Each panel shows the normalized 
spectrum of brain tissue (spaced dotted lines) together with the best 
fit (continuous line). The fit components are scaled by their relative 
contributions: components are category as in Table 2. Each category 
has a unique line type: ferrihydrite (dashed line), heme (double dot-
ted dashed line). See Table 2 for numerical results of the fits: q Quan-
titative analysis of Fe K-edge spectra in iron rich regions; r Quanti-
tative analysis of Fe K-edge spectra in iron-poor regions; Scale bars 
a–e 3 mm; Scale bars f–l 50 μm; Scale bars l inset, m–o 12.5 μm; 
Scale bar p 90 μm; Color scales b, e, p represent the normalized 
total Kα fluorescence counts, proportional to total metal present, from 




Fig. 7  Iron and zinc in shadow plaques (case 14 in Fig. 1a). The 
shadow plaques (asterisks) are seen as a milder immunoreactivity 
for myelin proteins (PLP), and b pale Luxol fast blue staining (LFB/
PAS); c Fe accumulates in one (black asterisk in a and b) of the two 
shadow plaques, but not the other one (white asterisk in a and b) 
(XFI); d The modified Turnbull stain shows a similar iron distribu-
tion (Fe histochemistry); e Zn is lost in the demyelinated lesion and 
shadow plaques (XFI); f The overlay of Fe and Zn shows the Fe accu-
mulation in one of the two shadow plaques (XFI); g Higher magni-
fication of the iron-accumulating (black asterisk in a and b) shadow 
plaque (Lfb/PAS); Oligodendrocytes with large nuclei are h positive 
for iron (Fe histochemistry), and i immunoreactive for H-ferritin 
(FTH) and L-ferritin (inset; FTL); j Higher magnification of the iron-
poor (white asterisk in a and b) shadow plaque (Lfb/PAS); k Oligo-
dendrocytes with normal sized nuclei in the iron-poor remyelinated 
lesion are immunoreactive for H ferritin (FTH) and L ferritin (inset; 
FTL); Scale bars a–f 3 mm; Scale bars g, j 500 μm; Scale bars h, i, 
k 20 μm; Color scales c, e represent the normalized total Kα fluores-
cence counts, proportional to total metal present, from blue (lowest) 
to red (highest); Color scale f represents the overlay of the normal-
ized total Fe and Zn Kα fluorescence counts, proportional to total 
metal present, from blue (Zn) to red (Fe)
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The relationship between iron metabolism diseases and 
MS is currently unknown. Although genetic hemochroma-
tosis does not increase MS severity [57], a recently devel-
oped hemochromatosis mouse model indicates that brain 
iron accumulation alters the myelin-related transcriptome 
[23, 24]. While this relationship may be elucidated by EAE 
induction in this model, the relevance to MS remains to be 
determined.
Our study highlights the limitations of iron histochem-
istry [38]. Although iron staining approximates well the 
XFI iron in iron-rich areas, it grossly underestimates iron 
in iron-poor lesions, normal appearing WM and periplaque 
WM. This is explained by the XFI’s high sensitivity and 
specificity for iron [52], and by XANES showing that 
iron-rich areas mostly contain ferric non-heme iron, while 
iron-poor regions contain more heme iron. Another limita-
tion which impacts both iron histochemistry and XFI is the 
use of formalin-fixed paraffin-embedded tissue. Formalin 
fixation is known to leach metals from tissues, although the 
extent of leaching is debatable [6, 7, 59]. Paraffin embed-
ding may also accentuate this phenomenon, and further 
oxidize metals, possibly accounting for why no ferrous 
iron was detected [21]. The limited number of cases from 
which XANES spectra have been collected is another study 
limitation. Nevertheless, these data are valuable and com-
plementary to ferritin immunohistochemistry, with both 
approaches indicating that most iron is safely stored in 
ferritin. Further studies need to establish whether our find-
ings are broadly applicable to iron accumulation in a larger 
cohort of smoldering and chronic plaques.
Conclusion
We describe novel findings with respect to the localization 
of iron and zinc in MS chronic lesions, and provide insights 
into the role of metals in MS lesion evolution and repair. 
Our findings highlight that iron and zinc homeostasis in MS 
pathogenesis is more complex and dynamic than previously 
reported in published pathological-radiographic correlative 
studies. We observed that while iron is decreased in most 
chronic MS lesions, there is a subset of smoldering and 
inactive lesions where reactive astrocytes safely accumulate 
ferric iron as ferrihydrite. Zinc in MS lesions is generally 
decreased, paralleling the myelin loss. We also show that 
not all smoldering rims contain iron and we describe a 
single chronic inactive lesion where iron accumulates 
concentrically within the lesion. Further studies are needed 
to determine whether MRI features reportedly associated 
with iron rims around smoldering and inactive plaques 
differ. Although our study focused on chronic non-active 
MS lesions, XFI-pathological correlative studies examining 
iron and zinc in actively demyelinating lesions are ongoing, 
to better define their role in early lesion formation. 
Understanding the balance and timing of trophic, toxic, and 
antioxidant effects of biometals in early and chronic MS is 
critical for developing pharmacological interventions that 
either facilitate repair or disrupt the chain of events caused 
by metal-induced oxidative stress and MS tissue injury. 
XFI-MRI correlative studies will permit development and 
validation of specific metal detection methods paving the 
way to novel metal-based biomarkers to monitor disease 
activity and progression in MS.
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